At AAN 2017, Aaron Miller, MD, Mount Sinai discussed results of the TOPIC trial that investigated the administration of (7 and 17mg) teriflunomide vs. placebo in multiple sclerosis patients with clinically isolated syndromes with a primary endpoint of the conversion to clinically definite multiple sclerosis, meaning a new relapse.

According to Miller, the pivotal portion of the double blind randomized trial demonstrated a 43% reduction in the conversion to clinically definite MS for the 14mg dose of teriflunomide. The TOPIC Extension trial then took patients who had been in the original, randomized trial and re-randomized the patients who completed that trial. The patients who were originally assigned to either 7 or 14mg of teriflunomide were continued on those doses and patients who had been originally assigned to placebo were re-randomized to either 7 or 14mg of teriflunomide.

0 Comments

Up next

Autoplay

Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix or Leuprolide

2 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

OPIC Extension Study: Teriflunomide a

Up next

Language